Ototoxicity clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 years and up
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.